Man Group’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $244M | Buy |
315,212
+97,100
| +45% | +$74.3M | 0.44% | 35 |
|
|
2025
Q4 | $168M | Sell |
218,112
-53,595
| -20% | -$36.4M | 0.29% | 73 |
|
|
2025
Q3 | $153M | Buy |
271,707
+195,724
| +258% | +$111M | 0.27% | 81 |
|
|
2025
Q2 | $39.9M | Buy |
75,983
+40,397
| +114% | +$22.5M | 0.08% | 292 |
|
|
2025
Q1 | $22.6M | Sell |
35,586
-558
| -2% | -$384K | 0.06% | 395 |
|
|
2024
Q4 | $25.7M | Sell |
36,144
-24,377
| -40% | -$20.5M | 0.07% | 342 |
|
|
2024
Q3 | $63.6M | Buy |
60,521
+8,777
| +17% | +$9.77M | 0.17% | 152 |
|
|
2024
Q2 | $54.4M | Sell |
51,744
-56,728
| -52% | -$55M | 0.14% | 163 |
|
|
2024
Q1 | $104M | Buy |
108,472
+14,912
| +16% | +$14.2M | 0.26% | 76 |
|
|
2023
Q4 | $82.2M | Buy |
+93,560
| New | +$77M | 0.23% | 93 |
|
|
2023
Q3 | – | Sell |
-116,636
| Closed | -$91.7M | – | 225 |
|
|
2023
Q2 | $83.8M | Buy |
+116,636
| New | +$89.9M | 0.26% | 80 |
|
|
2023
Q1 | – | Sell |
-77,120
| Closed | -$58.2M | – | 281 |
|
|
2022
Q4 | $55.6M | Buy |
77,120
+57,473
| +293% | +$42.4M | 0.2% | 113 |
|
|
2022
Q3 | $13.5M | Buy |
+19,647
| New | +$12.4M | 0.06% | 377 |
|
|
2022
Q2 | – | Sell |
-29,970
| Closed | -$19.5M | – | 257 |
|
|
2022
Q1 | $20.9M | Sell |
29,970
-117,219
| -80% | -$74.2M | 0.07% | 303 |
|
|
2021
Q4 | $93M | Buy |
147,189
+66,819
| +83% | +$41.1M | 0.3% | 62 |
|
|
2021
Q3 | $48.6M | Sell |
80,370
-28,583
| -26% | -$17.7M | 0.17% | 131 |
|
|
2021
Q2 | $60.9M | Sell |
108,953
-11,314
| -9% | -$5.73M | 0.21% | 97 |
|
|
2021
Q1 | $56.9M | Buy |
120,267
+74,920
| +165% | +$36.5M | 0.25% | 87 |
|
|
2020
Q4 | $21.9M | Buy |
45,347
+17,041
| +60% | +$9.2M | 0.1% | 204 |
|
|
2020
Q3 | $15.8M | Sell |
28,306
-5,658
| -17% | -$3.43M | 0.06% | 329 |
|
|
2020
Q2 | $21.2M | Buy |
33,964
+3,280
| +11% | +$1.86M | 0.11% | 184 |
|
|
2020
Q1 | $15M | Buy |
30,684
+2,363
| +8% | +$975K | 0.1% | 214 |
|
|
2019
Q4 | $10.6M | Buy |
28,321
+13,695
| +94% | +$4.61M | 0.04% | 665 |
|
|
2019
Q3 | $4.06M | Sell |
14,626
-2,383
| -14% | -$705K | 0.02% | 966 |
|
|
2019
Q2 | $5.33M | Buy |
17,009
+12,980
| +322% | +$4.32M | 0.02% | 923 |
|
|
2019
Q1 | $1.65M | Sell |
4,029
-1,647
| -29% | -$678K | 0.01% | 1406 |
|
|
2018
Q4 | $2.12M | Sell |
5,676
-490
| -8% | -$179K | 0.01% | 1197 |
|
|
2018
Q3 | $2.49M | Sell |
6,166
-74
| -1% | -$28.2K | 0.01% | 1324 |
|
|
2018
Q2 | $2.15M | Sell |
6,240
-41
| -0.7% | -$12.8K | 0.01% | 1334 |
|
|
2018
Q1 | $2.16M | Buy |
+6,281
| New | +$2.18M | 0.01% | 1252 |
|
Other funds holding REGN
VCM
N
Man Group's REGN Position: Q1 2026 in Review
Man Group increased its Regeneron Pharmaceuticals (REGN) stake by 45% in Q1 2026, buying an estimated $74.3M and bringing the position to 315,212 shares worth $244M. The position accounts for 0.44% of the portfolio, ranked #35.
Man Group first reported a position in REGN in Q1 2018 and has held it in 30 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Man Group held 315,212 shares of Regeneron Pharmaceuticals worth $244M as of Q1 2026.
- Man Group bought 97,100 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $74.3M.
- Regeneron Pharmaceuticals made up 0.44% of Man Group's portfolio in Q1 2026, its #35 holding.
- Man Group first reported a position in Regeneron Pharmaceuticals in Q1 2018 and has held it in 30 quarters since.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.